IKS Health reports 17% revenue growth in Q4FY25

Inventurus Knowledge Solutions Ltd, known as IKS Health, announced strong financial results for the quarter ended March 31, 2025, with revenue growing 17 per cent year-over-year in INR and 13 per cent in USD.

The shares of Inventurus were trading at ₹1,665.10, up by ₹11.20 or 0.68 per cent on the NSE today at 3.15 pm.

The healthcare solutions provider reported Q4 EBITDA of ₹226.2 crore, up 68 per cent from the previous year and 13 per cent quarter-over-quarter. Profit after tax (PAT) showed substantial growth at ₹147.8 crore, a 133 per cent increase year-over-year and 14 per cent quarter-over-quarter.

For the full fiscal year 2025, IKS Health posted revenue of ₹2,664 crore, representing 47 per cent year-over-year growth. EBITDA reached ₹791.1 crore, up 50 per cent from the previous year, while PAT stood at ₹486.1 crore, a 31 per cent increase year-over-year.

The company secured five major client wins during Q4, including three platform deals. Notable partnerships included Sky Lakes, Western Washington Medical Group, GI Alliance, Platinum Dermatology Partners, and OrthoNY.

“Our Q4 FY25 EBITDA margins have crossed 31 per cent, a significant improvement from the 24 per cent proforma margin of FY2024,” said Sachin K. Gupta, Founder & CEO of IKS Health.

Published on May 16, 2025